3 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 17914916 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | LU, CHENG | 1642 | Final Rejection | Sep 27, 2022 |
| 17914969 | EFFICACIOUS DOSE FOR HER2 BISPECIFIC ANTIBODY | DUFFY, BRADLEY | 1643 | Final Rejection | Sep 27, 2022 |
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | LEE, YIE CHIA | 1642 | Non-Final OA | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial